Keyword: Impax Laboratories

In an effort to keep drug prices down, California is looking to end a longtime pharma practice that keeps generic challengers off the market.

Facing pressure to its generics business and plummeting sales, Amneal has replaced its once-heralded chairman and his handpicked CEO in major shakeup.

Many years into an investigation over a "pay-for-delay" payment on Opana ER, the FTC says Impax violated competition law.

More turnover is coming to Allergan’s board—and this time, it’s the man who arguably built the company.

Teva's EpiPen copy will hit the market even as spot shortages of the ubiquitous auto injector have developed.

Privately held Kaléo has a supply of epinephrine auto injectors and is making sure the public knows its version is available.

India's Aurobindo has submitted a $1.6 billion offer for Novartis' generic dermatology assets in the U.S., according to Livemint.

Retailers settled claims that Impax made an illegal deal to delay its generic version of Solodyn, but insurer and consumer plaintiffs are fighting on.

Amneal CEO Chintu Patel expects to expand a plant in New York and add 400 employees as a merger with Impax nears.

Legend teams with J&J on CAR-T project, Eisai and Biogen's Alzheimer's drug fails in early readout, Impax and Bora Pharma ink deal.